Mizuho Securities Keeps Their Sell Rating on Pacira Pharmaceuticals (PCRX)


In a report released today, Irina Rivkind Koffler from Mizuho Securities maintained a Sell rating on Pacira Pharmaceuticals (PCRX), with a price target of $29. The company’s shares closed yesterday at $39.82.

Rivkind Koffler observed:

“We expect more clarity around the Heron delay on the company’s 8:30 AM call today.”

According to TipRanks.com, Koffler is a 4-star analyst with an average return of 5.5% and a 39.5% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Assertio Therapeutics Inc.

Currently, the analyst consensus on Pacira Pharmaceuticals is a Hold with an average price target of $49.43.

See today’s analyst top recommended stocks >>

Based on Pacira Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $8.29 million. In comparison, last year the company had a GAAP net loss of $10.68 million.

Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PCRX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Pacira Biosciences, Inc. operates as a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts